Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 29, 2026CancersOpen Access

Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJingyao ZhangLZLinjun ZhaRLRuqiang Liang

Discussion

Loading...

Member takes

Overview

Review highlights EGFR mutation prevalence and clinical implications in non-small-cell lung cancer, suggesting improved treatment strategies.

Key Points

  • To explore the prevalence and clinical implications of somatic and germline EGFR mutations in non-small-cell lung cancer.
  • Review of diagnostic and therapeutic advancements for EGFR-mutant NSCLC
  • Analysis of the role of somatic and germline mutations in disease evolution
  • Discussion of the importance of genetic counseling and testing in identifying germline mutations
  • Somatic EGFR mutations are crucial biomarkers that guide treatment decisions and disease management.
  • Germline EGFR alterations, especially T790M, are linked to inherited lung cancer susceptibility, highlighting a new hereditary cancer phenotype.
  • Early identification of germline mutations can improve clinical outcomes and inform treatment strategies.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a69a25ec8da07d9defa5b62https://doi.org/10.3390/cancers18152417
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Systemic treatment of EGFR-mutated non-small cell lung cancer2024
  2. 2Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management2025 · 22 citations
  3. 3Germline EGFR T790M in Lung Cancer: Prevalence, Clinical Impact, and Implications for Hereditary Risk2025 · 2 citations
  4. 4Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis.2026
  5. 5From missed mutations to liquid clues: a new era of EGFR diagnostics in NSCLC2025